Temab-A联合贝伐珠单抗对比FTD-TPI联合贝伐珠单抗治疗转移性结直肠癌的随机1期研究
该随机1期研究在未筛选c-Met表达的晚期结直肠癌患者中,评估Temab-A联合贝伐珠单抗对比FTD-TPI联合贝伐珠单抗的疗效与安全性。结果显示Temab-A 2.4 mg/kg联合贝伐珠单抗的客观缓解率、无进展生存期和总生存期均优于标准治疗,且耐受性可管理。
要点
- Temab-A 2.4 mg/kg联合贝伐珠单抗的客观缓解率为30%,FTD-TPI联合贝伐珠单抗为0%。
- Temab-A 2.4 mg/kg联合贝伐珠单抗中位无进展生存期6.8个月,总生存期14.7个月(HR=0.62)。
- Temab-A联合贝伐珠单抗治疗相关不良事件以胃肠道和血液学为主,停药率低。
核心结论
- Temab-A 2.4 mg/kg联合贝伐珠单抗在晚期结直肠癌中显示出最有利的风险获益特征,耐受性可接受,疗效优于FTD-TPI联合贝伐珠单抗。
研究设计与样本
- 随机1期研究,纳入未筛选c-Met蛋白表达的晚期结直肠癌患者,分剂量递增和剂量优化两部分。
- 剂量递增阶段患者接受Temab-A 1.6、2.0或2.4 mg/kg联合贝伐珠单抗7.5 mg/kg每3周一次。
- 剂量优化阶段患者按1:1:1随机接受Temab-A 2.0或2.4 mg/kg联合贝伐珠单抗7.5 mg/kg每3周一次,或FTD-TPI 35 mg/m2第1-5天和第8-12天每4周一次联合贝伐珠单抗5.0 mg/kg每2周一次。
- 共83例患者接受治疗:Temab-A联合贝伐珠单抗组63例,FTD-TPI联合贝伐珠单抗组20例;中位既往治疗线数3(范围1-8),中位随访18.2个月。
主要发现
- Temab-A 2.0和2.4 mg/kg联合贝伐珠单抗的客观缓解率分别为19%和30%,FTD-TPI联合贝伐珠单抗为0%。
- Temab-A 2.0和2.4 mg/kg联合贝伐珠单抗 vs FTD-TPI联合贝伐珠单抗的中位无进展生存期分别为5.6和6.8个月 vs 4.2个月。
- Temab-A 2.0和2.4 mg/kg联合贝伐珠单抗 vs FTD-TPI联合贝伐珠单抗的中位总生存期分别为11.2个月(HR=0.75)和14.7个月(HR=0.62) vs 10.2个月。
- 治疗相关不良事件主要为胃肠道和血液学毒性,停药率低:Temab-A 2.0组3/26(12%),Temab-A 2.4组1/30(3%)。
关键数值与推荐
- Temab-A 2.4 mg/kg联合贝伐珠单抗7.5 mg/kg每3周一次为剂量优化阶段选择的最有利风险获益方案。
- 该方案正在全球随机3期试验AndroMETa-560(NCT07525206)中进一步评估。
临床怎么用
- 对于既往多线治疗的晚期结直肠癌患者,Temab-A 2.4 mg/kg联合贝伐珠单抗可能提供优于FTD-TPI联合贝伐珠单抗的疗效,且安全性可管理。
- 治疗期间需关注胃肠道和血液学不良事件,但停药率较低。
局限性
- 本研究为1期随机研究,样本量较小(共83例),结果需3期试验验证。
- 患者未筛选c-Met蛋白表达,疗效与c-Met表达水平的关系未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Telisotuzumab adizutecan (ABBV-400, Temab-A) is an antibody-drug conjugate targeting c-Met (MET) protein with adizutecan, a novel topoisomerase 1 inhibitor payload. In monotherapy dose escalation, Temab-A demonstrated a manageable safety profile and promising antitumor activity in advanced colorectal cancer (CRC; NCT05029882). Based on these results, a randomized cohort of Temab-A + bevacizumab (Bev) versus trifluridine-tipiracil (FTD-TPI) + Bev (standard-of-care) was added with the hypothesis that addition of Bev would enhance efficacy. PATIENTS AND METHODS: Patients unselected for c-Met protein expression with advanced CRC were enrolled in 2 parts. In dose escalation, patients received Temab-A 1.6, 2.0, or 2.4 mg/kg + Bev 7.5 mg/kg Q3W. In dose optimization, patients were randomized 1:1:1 to Temab-A 2.0 or 2.4 mg/kg + Bev 7.5 mg/kg Q3W, or FTD-TPI 35 mg/m2 Days 1-5 and 8-12 Q4W + Bev 5.0 mg/kg Q2W. Primary objectives were safety, pharmacokinetics, and efficacy of Temab-A + Bev. RESULTS: Overall, 83 patients received treatment with Temab-A + Bev (n=63) or FTD-TPI + Bev (n=20) with median 3 (range, 1-8) prior lines of treatment and median follow-up of 18.2 months. Treatment-related adverse events were primarily gastrointestinal and hematological with low discontinuation rates (Temab-A 2.0: 3/26 [12%]; Temab-A 2.4: 1/30 [3%]). Objective response rate was 19% and 30% with Temab-A 2.0 and 2.4 + Bev, respectively, and 0% with FTD-TPI + Bev. For Temab-A 2.0 and 2.4 + Bev vs FTD-TPI + Bev, median progression-free survival was 5.6 and 6.8 months vs 4.2 months; median overall survival was 11.2 (HR=0.75) and 14.7 months (HR=0.62) vs 10.2 months, respectively. CONCLUSION: Temab-A 2.4 mg/kg + Bev demonstrated the most favorable risk-benefit profile, was tolerable, and had clinically meaningful improvements in efficacy versus FTD-TPI + Bev for advanced CRC. The regimen is being evaluated in the global randomized Phase 3 trial AndroMETa-560 (NCT07525206).
引用
- Cecchini M, Cruz-Correa M, Han SW, et al. A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer. Ann Oncol. 2026. PMID: 42926107. doi:10.1016/j.annonc.2026.10.105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。